marketing strategies in order to seek more non-hazardous waste put into the RDF process as well as to improve the sales planning by seeking more buyers such as cement factory, power plant etc. At present, the

proceeded with its initial investment plans to install new machines in the second-phase capacity expansion for the new factory, which was already completed in the end of Q2/2019 in time to support the

from the fixed cost control at the factory. Distribution Costs The company has the distribution costs in the second quarter in the amount of 197.2 million Baht or equal to 15.1 percent of revenue from

103.5 MB from new factory construction paid. 2. Non-current assets As of year-end 2017 and Q1/2018 the company’s non-current assets totaled THB 255.5 MB and THB 434.0 MB and equivalent to 19.9% and 35.7

80.95 million from the factory which is under construction. The withholding tax increased by Baht 11.59 million due to a decrease in adjusting of available for sale of securities. Liabilities As at 31

equivalent to 39.1% and 19.4% of the total assets respectively. The main current assets decrease in inventory of THB 304.9 MB and decrease in cash and cash equivalents of THB 151.2 MB from new factory

decrease in cash and cash equivalents of THB 294.4 MB from new factory construction paid. 2. Non-current assets As of year-end 2017 and Q3/2018 the company’s non-current assets totaled THB 255.5 MB and THB

and service was come from leasing space of warehouse/factory in Bangkok Free Trade Zone Project (by Prospect Development Co., Ltd.) for an amount of THB 52.43, THB 6.12 million or 13.21% higher than the

Laboratories Co., Ltd. is a listed company established in the year 1971. The manufacture and distribution of conventional medicine. Office and Factory are located at No.47 Soi Boonchana, Sukhumvit 59, Klong Ton

line at the US factory was discontinued and changed to outsourced production instead, and thanks to the reduced production capacity, the unit production costs were relatively increased from last year